Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LSTA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Absence of Committed Financing (new) — Acquirer lacks committed funding as of amendment date, creating material uncertainty about deal completion.
- Failure to Commence the Offer By June 1, 2026 (new) — Buyer missed contractual tender offer deadline, requiring waiver and extension.
- Failure to Pay the Interim Operating Payment (new) — Buyer missed $250,000 payment due May 26, requiring waiver and restructured payment schedule.
Lisata extends merger deadlines as Kuva Labs lacks committed financing, waives breach claims
Filed June 9, 2026 · Period ending June 8, 2026 · ~2 min read
Key Changes
-
high
Kuva Labs acknowledged it has no committed financing for the acquisition as of June 8. The buyer must disclose this material fact and any financing changes to shareholders, creating significant deal completion risk.
Item 1.01 - Amendment verify on EDGAR → -
high
Lisata waived breach claims after Kuva missed the June 1 tender offer deadline and failed to pay a $250,000 operating payment due May 26. Kuva will make two catch-up payments totaling $250,000 by June 26.
Item 1.01 - Waiver verify on EDGAR → -
high
Merger closing deadline extended from July 1 to July 17, 2026. Kuva can pay a non-refundable $1.5 million fee to extend further to August 17, suggesting the buyer needs more time to arrange financing.
Item 1.01 - Amendment verify on EDGAR → -
high
Tender offer now scheduled to commence June 10 (delayed from June 1). The offer has not yet started, and shareholders should wait for Schedule TO and 14D-9 filings before making decisions.
Item 8.01 - Status view on EDGAR → -
medium
Lisata can terminate all waivers and extensions if Kuva misses any payment under the amendment or commits an uncured material breach within two business days of notice.
Item 1.01 - Termination Rights verify on EDGAR →
Summary
Lisata Therapeutics amended its merger agreement with Kuva Labs on June 8, extending critical deadlines after the buyer missed multiple obligations. Most significantly, Kuva acknowledged it lacks committed financing for the acquisition—a material fact that must be disclosed to shareholders considering whether to tender their shares.
The tender offer, originally due June 1, has been pushed to June 10, and the merger closing deadline extended from July 1 to July 17 (with an option to extend to August 17 for a $1.5 million fee). Lisata also waived breach claims after Kuva failed to pay a $250,000 operating payment due May 26 and missed the original tender deadline. In exchange, Kuva will make catch-up payments totaling $250,000 by June 26.
While Kuva committed to use best efforts to secure alternative financing if needed, the absence of committed funding represents significant deal risk. Lisata retained termination rights if Kuva misses future payments or commits material breaches. Shareholders should watch for the Schedule TO filing when the tender offer commences and Lisata's Schedule 14D-9 recommendation. The financing disclosure and repeated deadline extensions suggest meaningful execution risk. Monitor whether Kuva secures committed financing and meets the June payment deadlines—failure on either front could jeopardize the transaction.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Lisata amended its merger agreement with Kuva Labs, extending tender offer and closing deadlines while waiving certain breach claims.
Added in current filing · verify on EDGAR →
Upon commencement of the Offer, the Company shall irrevocably waive any claims to the extent arising from or relating to the Purchaser’s failure to commence the Offer by June 1, 2026. Upon the commencement of the Offer and provided that the Parent pays to the Company (i) $150,000 on June 12, 2026 and (ii) $100,000 on June 26, 2026, the Company shall irrevocably waive any claims to the extent arising from or relating to the Purchaser’s failure to pay the interim operating payment of $250,000 that was due to the Company on May 26, 2026.
Lisata agreed to waive breach claims against Kuva $150,000 for missing the June 1 tender offer deadline and $100,000 for failing to pay a $250,000 interim operating payment due May 26. In exchange, Kuva will make two payments totaling $250,000 on June 12 and June 26. This indicates the buyer previously missed contractual obligations, raising questions about deal execution risk.
Added in current filing · verify on EDGAR →
Purchaser acknowledged and agreed that (i) the absence of committed financing as of the date of the Amendment constitutes information that is material to security holders of the Company for purposes of their decision whether to tender their shares, (ii) Purchaser has disclosed and will continue to disclose this fact in accordance with all applicable requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, including in the Schedule TO and any amendments thereto, and (iii) to the extent that the financing status of the Offer changes in a manner that constitutes a material change under applicable Law, Purchaser shall promptly file an amendment to the Schedule TO disclosing such change
Kuva acknowledged it lacks committed financing for the acquisition as of the amendment date. The buyer committed to disclose this material fact and any financing status changes to Lisata shareholders. This represents significant deal risk, as the transaction depends on Kuva securing financing that is not yet in place.
Added in current filing · verify on EDGAR →
Parent and Purchaser also made certain representations and agreed to certain covenants regarding its anticipated sources of financing, including agreeing to use its best efforts to arrange and obtain alternative financing from alternative sources if its anticipated sources of financing become unavailable.
Kuva agreed to use best efforts to secure alternative financing if its current anticipated sources fall through. This covenant provides some protection to Lisata but underscores the uncertainty around deal funding.
Event · Item 9.01 — Financial Statements and Exhibits
Lisata Therapeutics amended its merger agreement with Kuva Labs; tender offer has not yet commenced.
Added in current filing · verify on EDGAR →
Amendment and Waiver to Agreement and Plan of Merger, dated June 8, 2026, by and among Lisata Therapeutics, Inc., Kuva Labs Inc. and Kuva Acquisition Corp.
Lisata Therapeutics executed an amendment and waiver to its existing merger agreement with Kuva Labs Inc. and Kuva Acquisition Corp. on June 8, 2026. The specific terms of the amendment and waiver are not disclosed in this 8-K, but the filing indicates that a tender offer related to the proposed acquisition has not yet commenced.
Added in current filing · verify on EDGAR →
The tender offer referred to in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Parent and Purchaser will file with the SEC upon commencement of the tender offer, if commenced at all.
The company explicitly states that the tender offer for the proposed acquisition has not yet started. When and if the tender offer commences, Kuva Labs (Parent) and its acquisition subsidiary (Purchaser) will file a Schedule TO with the SEC, and Lisata will file a Schedule 14D-9 recommendation statement. Stockholders are advised to wait for these materials before making any decisions.
Added in current filing · verify on EDGAR →
risks associated with the timing of the commencement of the tender, including the risk that Parent may not commence the tender offer promptly or at all; risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all, the risk that Parent or Purchaser may not obtain financing for the transaction within the expected timeframe or at all or the risk that the closing of the proposed transaction will not occur
The filing discloses significant risks to the transaction's completion, including the possibility that the tender offer may never commence, that closing conditions may not be satisfied, or that the acquirer may fail to obtain necessary financing. These are material uncertainties that could result in the deal not closing at all.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify